ArticleNature communications2021
CRISPR-based genome editing in primary human pancreatic islet cells.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 53 citations in OpenAlex.
- CRISPR Technologies in Type 2 Diabetes: From Mechanistic Insights to Therapeutic Discovery.International journal of molecular sciences · 2026Review
- CRISPR-Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus.Molecular biology reports · 2026Review
- pertTF: context-aware AI modeling for genome-scale and cross-system perturbation prediction.bioRxiv : the preprint server for biology · 2026Article
- eVLP-Mediated Cas9 Delivery for Preventing IBMIR in Islet Transplantation.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Review
- The Role of Gene Therapy and RNA-Based Therapeutic Strategies in Diabetes.International journal of molecular sciences · 2025Review
- Metabolic STAMP for deciphering GPCR-regulated insulin secretion by pancreatic β cells.bioRxiv : the preprint server for biology · 2025Article
- Efficient transduction of pancreas tissue slices with genetically encoded calcium integrators.bioRxiv : the preprint server for biology · 2025Article
- Subaqueous acoustic pressure system based one day heterotypic pseudo-islet spheroid formation with adipose derived stem cells for graft survival-related function enhancement.Bioactive materials · 2025Article
- Strategies for optimization of hypoglycemia rat models.Animal models and experimental medicine · 2025Review
- MicroRNAs in diabetes mellitus.Journal of diabetes and metabolic disorders · 2025Review
- Advancements in CRISPR/Cas systems for disease treatment.Acta pharmaceutica Sinica. B · 2025Review
- Excess of rare noncoding variants in several type 2 diabetes candidate genes among Asian Indian families.Communications medicine · 2025Article
- Bcl-2 and Bcl-xL in Diabetes: Contributions to Endocrine Pancreas Viability and Function.Biomedicines · 2025Review
- Harnessing beta-cell replication: advancing molecular insights to regenerative therapies in diabetes.Frontiers in endocrinology · 2025Review
- Advancing diabetes management: Exploring pancreatic beta-cell restoration's potential and challenges.World journal of gastroenterology · 2024Review
- Comparison between capillary electrophoresis and fluorescence anisotropy competitive immunoassay for glucagon.Electrophoresis · 2024Article
- Untangling the genetics of beta cell dysfunction and death in type 1 diabetes.Molecular metabolism · 2024Review
- β-cell neogenesis: A rising star to rescue diabetes mellitus.Journal of advanced research · 2024Review
- Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoprotein.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 4 countries.
Romina J BevacquaDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA.
Xiaoqing DaiAlberta Diabetes Institute and Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
Jonathan Y LamDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-9579-0604
Xueying GuDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA.
Mollie S H FriedlanderDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA.
Krissie TellezDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA.
Irene Miguel-EscaladaBioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0003-3461-6404
Silvia Bonàs-GuarchBioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0002-2085-7488
Goutham AtlaBioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Weichen ZhaoDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA.
Seung Hyun KimDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA.
Antonia A DominguezDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3965-3223
Jorge FerrerBioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0002-5959-5729
Patrick E MacDonaldAlberta Diabetes Institute and Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
Seung K KimDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, USA. seungkim@stanford.edu.ORCID http://orcid.org/0000-0001-6135-7810
Stanford University · USCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESUniversity of Alberta · CANorthern California Research · USStanford Medicine · US
Funding
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3MThe Human Islet Distribution Coordinating Center (UC4)UC4DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI EVANS-MOLINA, CARMELLA, NILAND, JOYCE CAROL · 2012 to 2017
$25.6MStanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5MTherapeutic targeting of human islets with recombinant regulatory T cellsU01DK123743 · NIDDK · STANFORD UNIVERSITY · PI KIM, SEUNG K, MEYER, EVERETT · 2019 to 2022
$2.9MGenetic and physiologic regulation of pig islet development and functionR01DK128932 · NIDDK · STANFORD UNIVERSITY · PI BERGER, TRISH, KIM, SEUNG K · 2021 to 2024
$2.6MIn vivo systems to discover mechanisms regulating human islet alpha cell functionR01DK126482 · NIDDK · STANFORD UNIVERSITY · PI KIM, SEUNG K, MACDONALD, PATRICK · 2020 to 2023
$2.2MRegulation of gastrointestinal hormone signaling and metabolism by Neuromedin UR01DK107507 · NIDDK · STANFORD UNIVERSITY · PI KIM, SEUNG K · 2017 to 2021
$2.0MDiscovering genetic and hormonal mechanisms underlying diabetes risk from flies to humansR01DK108817 · NIDDK · STANFORD UNIVERSITY · PI KIM, SEUNG K · 2018 to 2022
$2.0MMedical Research Council MR/L02036X/1NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK107507NIDDK NIH HHS R01 DK108817NIDDK NIH HHS R01 DK126482NIDDK NIH HHS R01 DK128932NIDDK NIH HHS U01 DK123743NIDDK NIH HHS UC4 DK098085Wellcome TrustWellcome Trust WT101033
Abstract
Gene targeting studies in primary human islets could advance our understanding of mechanisms driving diabetes pathogenesis. Here, we demonstrate successful genome editing in primary human islets using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9). CRISPR-based targeting efficiently mutated protein-coding exons, resulting in acute loss of islet β-cell regulators, like the transcription factor PDX1 and the K
Indexed as
CRISPR-Cas SystemsModels, GeneticBase SequenceDiabetes Mellitus, Type 2Gene EditingGene Expression RegulationHomeodomain ProteinsHumansInsulin-Secreting CellsIslets of LangerhansKcnj11 ChannelPotassium Channels, Inwardly RectifyingTrans-ActivatorsHomeodomain ProteinsKcnj11 Channelpancreatic and duodenal homeobox 1 proteinPotassium Channels, Inwardly RectifyingTrans-Activators
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.